Geographic atrophy

This study tests the safety of a drug called ASP3021 (avacincaptad pegol) for people in Japan with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. Twenty participants will receive monthly injections into the affected eye for 12 mo…

This early-stage trial is testing a new drug called VOY-101 for people with advanced dry age-related macular degeneration (AMD) and geographic atrophy, a condition that causes blind spots. The drug is injected into the eye and aims to slow damage to the retina and preserve vision…

This study tests a gene therapy called OCU410 for geographic atrophy, a severe form of dry age-related macular degeneration that causes vision loss. About 60 adults aged 50 and older will receive a single injection of OCU410 into the eye. Researchers will monitor safety and check…

This study tests a drug called BI 1584862 in 150 adults aged 50+ with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo for 1 year. Doctors track changes in the retina using special …

This study tests a device called the PRIMA System, which includes an implant placed under the retina and a special visual processor worn by the patient. The goal is to help people with advanced dry age-related macular degeneration (geographic atrophy) regain some central vision. …

This study looks at how safe and tolerable the drug pegcetacoplan (Syfovre) is for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 300 patients who are already prescribed the drug by their doctor will be followed …

This study planned to test a small telescope implant inside the eye for people with severe vision loss from advanced age-related macular degeneration (AMD). The device was meant to improve central vision by magnifying images onto healthy parts of the retina. However, the trial wa…

This study tests a new medicine called BI 771716 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 202 adults aged 50 and older will receive either the new drug or an existing treatment (pegcetacoplan) as eye injections. T…

This study tests whether monthly eye injections of ANX007 can prevent significant vision loss in people with dry age-related macular degeneration (AMD) that has progressed to geographic atrophy. About 659 participants will receive either the drug or a sham injection. The main goa…

This Phase 3 trial tests whether a daily pill called tinlarebant can slow the growth of geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. About 429 adults with the condition will receive either the drug or a placebo for up to 2 year…

This study tests a device that uses real-time sound feedback to help people with vision loss fix their gaze on a target. Participants hear sounds that guide their eyes back to center when they drift. The goal is to improve the quality of eye imaging by reducing blur from eye move…

This study explores whether combining three eye-imaging techniques can reveal how structural damage in the retina relates to vision loss in people with geographic atrophy, a form of age-related macular degeneration. Researchers will use OCT scans, ultra-high-resolution AOSLO imag…